Sandoz spin-off continues Novartis’ focus on innovation; $22bn purchase rumoured
Both Sandoz and Novartis are internationally renowned pharma companies, with a total of 34 production facilities worldwide.
By
Comment
Latest in
Comment
Drug developers look at innovative mechanisms to tackle dry eye syndrome
As late-stage therapies for DES progress through clinical development, physicians and patients grow increasingly excited.
By
Micro-robots, smart toilets, and 3D bioprinted organs: the future of healthcare
With the personalised medicine market reaching $93bn by 2030, there will be a range of treatments available.
ByRNA sequencing developments may provide non-invasive diagnostics for endometriosis patients
Endometriosis is a disease characterized by endometrial-like tissue found outside of the uterus, resulting in symptoms such as chronic pelvic…
By
Cell-based therapies set to become major players in the osteoarthritis market
The development of disease-modifying osteoarthritis drugs is thought to be the greatest current unmet need in osteoarthritis.
By
Top biopharmaceutical Covid-19 vaccine companies boosted with over 80% revenue growth
The top biopharmaceutical companies that developed effective vaccines for Covid-19 during the pandemic reaped success last year.
By
ESMO 2022: anti-CD25 mAbs—an exciting immunotherapy in the pipeline
Multiple studies have reported high levels of tumour-infiltrating regulatory T cells to correlate with adverse patient outcomes.
By
Exploring opportunity and unmet needs in busy ulcerative colitis space
Developing drugs that avoid systemic immune modulation could be an area of growth in the ulcerative colitis therapeutics market.
By